Vertex fails to reach CF deal in Scotland

Two of Vertex's cystic fibrosis drugs continue to remain unavailable in the U.K. after the Scottish Medicines Consortium rejected their coverage on NHS, citing a lack of long-term data to support the price.

"As these are orphan medicines, our committee members were able to apply additional flexibility in their decision making, but there remained significant uncertainty around their overall health benefits in the long term in relation to their costs," SMC said Monday...